Evidence map›Paper›PMID 39162959›Full record

ArticleMycotoxin research2024

Ochratoxin a levels in Turkish coffee: a probabilistic health risk assessment via Monte Carlo simulation.

Sumeyra Sevim, Arife Macit, Mevlude Kizil

Abstract read
PubMed Publisher
In one paragraph

Article in Mycotoxin research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sumeyra SevimDepartment of Nutrition and Dietetics, Ankara Medipol University, Ankara, Turkey.ORCID http://orcid.org/0000-0001-9724-2628
Arife MacitDepartment of Nutrition and Dietetics, Hacettepe University, Ankara, Turkey.ORCID http://orcid.org/0000-0002-3717-2725
Mevlude KizilDepartment of Nutrition and Dietetics, Hacettepe University, Ankara, Turkey. mkizil@hacettepe.edu.tr.ORCID http://orcid.org/0000-0003-1380-3243

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Throughout history, Turkish coffee has been the most widely consumed type of coffee in Turkey. Therefore, the goal of this study was to determine the amount of ochratoxin A (OTA) present in Turkish coffee and to analyze any potential health hazards. A total of 41 Turkish coffees were collected and analyzed for OTA activity using a competitive enzyme immunoassay (ELISA). Furthermore, dietary exposure and health risk assessments for the Turkish population were calculated based on analytical results and coffee consumption data from the Turkish Nutrition and Health Survey 2019 (TNHS-2019) in three age categories (15-18, 19-64, and 65 + years). Nine of the samples contained more than 2.5 μg/kg OTA, with an average of 5.24 μg/kg. The OTA concentration in 3 samples exceeded the permissible maximum limit (5 μg/kg) established by Turkish legislation, and the mean concentration was 8.41 μg/kg. A margin of exposure (MOE) approach was used for risk characterization, considering both non-neoplastic and neoplastic consequences. There were no concerns about health risks because MOEs were more than 10,000 for all categories. Although the levels of OTA analyzed in Turkish coffee did not pose a risk to individuals in the three age categories, emphasis should be placed on minimizing and controlling OTA concentrations in Turkish coffee. Additionally, it is also necessary to consider other food sources that could contribute to OTA exposure.

Indexed as

CoffeeFood ContaminationOchratoxinsAdolescentAdultAgedDietary ExposureHumansMiddle AgedMonte Carlo MethodRisk AssessmentTurkeyYoung AdultCoffeeochratoxin AOchratoxinsExposureOchratoxin ARisk assessmentTurkish coffee

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.